Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Fair value of contingent consideration	$ 322,385	$ 0
Bayon acquisition | Successful completion of Phase 1b $0.495 million
Business Acquisition [Line Items]
Fair value of contingent consideration	500,000
Bayon acquisition | Successful completion of Phase 2 $0.990 million
Business Acquisition [Line Items]
Fair value of contingent consideration	1,000,000.0
Bayon acquisition | Successful completion of Phase 3 $4 million
Business Acquisition [Line Items]
Fair value of contingent consideration	4,000,000.0
Bayon acquisition | FDA approval
Business Acquisition [Line Items]
Fair value of contingent consideration	1,700,000
Panoptes acquisition | FDA approval
Business Acquisition [Line Items]
Fair value of contingent consideration	4,800,000
Panoptes acquisition | Beginning of Phase 3
Business Acquisition [Line Items]
Fair value of contingent consideration	4,800,000
Jade acquisition | FDA approval
Business Acquisition [Line Items]
Fair value of contingent consideration	$ 2,200,000